Introduction: The Questions a Financial Model Leaves Out

Medical device deals are often modeled like other product businesses. Revenue, margins and operations get close attention. The questions that decide whether a device reaches the market and stays there, such as the regulatory pathway, the clinical evidence, reimbursement and the quality system, can get less.

Consider a cardiac monitoring company with early revenue. The model may assume a regulatory timeline that precedent does not support, a predicate FDA may not accept, or payment the reimbursement record does not show. None of those is a financial question, but each one changes what the business is worth.

This guide groups medical device diligence into four areas: clinical and regulatory, technical and IP, commercial, and team and execution. For each, it lists the questions a deal team should ask and, where they exist, the public records that help answer them. It does not score a company or predict an outcome; it sets out what to look at.

The Four Areas of Medical Device Due Diligence

Each area carries its own risks, and a gap in one can undo strength in another:

A. Clinical and Regulatory

Regulatory Pathway

Most devices that need FDA review before marketing reach the U.S. market through one of three routes: a 510(k) premarket notification, which relies on a predicate device; a De Novo classification request, for a novel device with no predicate; or premarket approval (PMA), the pathway for most Class III devices. FDA's review goal for a 510(k) is 90 FDA days and for a De Novo request 150 review days. Total time to market also includes preparing the submission and any testing or clinical work behind it; see De Novo vs 510(k).

Breakthrough Device designation is not a separate pathway. It is a program for eligible devices that are also subject to a 510(k), De Novo request or PMA, generally those that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. FDA says it decides a designation request within 60 calendar days. A plan that depends on designation should show what happens if it is not granted.

Questions to ask:

• Which pathway does the company plan to use, and what precedent supports it?
• For a 510(k), is the predicate a legally marketed device with the same intended use, and how are the technological differences addressed? See Predicate Device Strategy.
• Has the company used a Pre-Submission to get FDA feedback on its plan, and what did that feedback say?
• If Breakthrough designation is part of the plan, has it been granted, and what is the plan without it?
• Do the timeline assumptions match the precedent for comparable devices, rather than the company's own projection?

Clinical Evidence and Safety

How much clinical evidence a device needs depends on its risk, its pathway and how different it is from devices already on the market. A clinical study of a significant risk device needs an investigational device exemption (IDE) approved by FDA as well as institutional review board approval; a nonsignificant risk study needs IRB approval (21 CFR 812). See Clinical Trial Design for Medical Devices.

Questions to ask:

• What clinical evidence exists today: bench and animal testing, feasibility studies, publications?
• If a pivotal study is needed, what are its primary endpoint, sample-size rationale and enrollment assumptions?
• Does the study involve a significant risk device, and if so, has FDA approved the IDE?
• Does the evidence support the specific indication being marketed, rather than a broader one?
• What postmarket obligations could follow, such as post-approval requirements on a PMA or a Section 522 order, which generally runs up to 36 months? See Post-Marketing Surveillance.

Clinical Differentiation

Statistical significance is not the same as a difference clinicians or hospitals will act on. A modest accuracy gain may matter less to adoption than a faster workflow, less sample preparation or a lower cost. The question is what the device changes for the people who use it.

Questions to ask:

• What is the clinical advantage over the current standard of care, and is it documented?
• Does the advantage matter to the people who choose the device: clinicians, hospitals, patients?
• Is there published outcome evidence, from the company or others, behind the claimed advantage?
• How easily could a larger company replicate the mechanism?

B. Technical and IP

Technical risk is where engineering, IP and manufacturing meet. A sound device concept can still stall on a weak IP position or an underestimated scale-up.

IP Position

A patent count says little on its own. What matters is what the claims cover, whether they read on the commercial product, and whether anyone else's patents do.

Questions to ask:

• Which patents are issued and which are pending, in the U.S. and in the other markets the company plans to enter?
• Do the claims cover the commercial product and its key mechanism, or only an earlier version or a narrow feature?
• Is any core IP licensed, for example from a university, and on what terms?
• Have freedom-to-operate questions been analyzed, and by whom?
• Are any patents subject to an inter partes review or a reexamination?
• Does trade-secret know-how, such as manufacturing process knowledge, add to the position?

Design Maturity and Manufacturing Readiness

There is a long way between a bench prototype and consistent commercial production, and design transfer, process validation and supplier qualification are where that distance shows. Device manufacturers are subject to FDA's Quality Management System Regulation (21 CFR Part 820), which incorporates ISO 13485:2016 by reference and took effect on February 2, 2026. See Manufacturing Due Diligence.

Questions to ask:

• Where is the design: bench prototype, clinical-build units, or a design transferred to production?
• Have clinical or commercial units been built, how many, and at what yields?
• Are key components sourced from qualified suppliers, and are any single-source?
• Is manufacturing in-house or with a contract manufacturer, and is that manufacturer registered with FDA?
• What design and development documentation exists: design inputs and outputs, verification and validation reports, risk management files?

Scalability and Supply Chain

Unit cost does not fall automatically with volume. A design that is expensive to build at low volume can stay expensive at scale if the process, materials or tolerances do not change.

Questions to ask:

• What is the current manufacturing capacity, and what is the plan to scale it?
• Which suppliers are single-source, and what happens if one fails?
• Does the supply chain support the planned inventory approach?
• What is the current gross margin, and what assumptions drive it at higher volumes?

C. Commercial

A cleared or approved device still needs clinicians to use it, hospitals to buy it and payers to pay for it.

Reimbursement

Coding, coverage and payment are separate problems. A CPT or HCPCS code does not guarantee that a payer covers the procedure, and coverage does not set the payment rate. FDA clearance or approval settles none of the three. See The Reimbursement Question and the CMS Coverage Determination Guide.

1. Coding — Is there a code that describes the procedure or the device?
2. Coverage — Will Medicare, Medicaid and commercial payers cover it, and under what conditions?
3. Payment — How much will they pay, and does that support the business?

Questions to ask:

• Is there an existing CPT or HCPCS code that fits the procedure, or will the company need a new one?
• Does a Medicare national or local coverage determination apply, and what does it require?
• Could coverage come with evidence conditions? Under Coverage with Evidence Development, CMS can cover an item or service through a national coverage determination only in the context of a clinical study.
• What do payers pay today for the current standard of care?
• What timing does the model assume between clearance and payment, and what supports it?
• Is health economic evidence planned or underway?

Market Size and Addressable Opportunity

A top-down total addressable market figure says little about adoption. A bottom-up estimate built from the patient population, current treatment and realistic uptake is easier to test.

Questions to ask:

• How many patients have the target condition, and how many are treated today?
• What does the current standard of care cost, and who pays for it?
• What penetration does the model assume over time, and what supports those assumptions?
• Could the device address other indications, and would each need its own regulatory submission?
• Which markets outside the U.S. are planned, and what do their regulatory requirements involve? See the EU MDR update.

Competitive Landscape

A market that looks open today can have several competitors by the time a device launches.

Questions to ask:

• Who are the current competitors, and how established are they?
• Are larger companies developing similar devices? ClinicalTrials.gov and FDA's databases are a place to start.
• Is the device's advantage defensible, or easy to copy?
• Could the company hold its price if a competitor undercuts it?

D. Team and Execution

A sound clinical and commercial plan still depends on the people carrying it out.

FDA and Regulatory Experience

A team that has taken devices through FDA review knows what reviewers ask for and how reviews run. That experience is worth checking rather than assuming.

Questions to ask:

• Who on the team has led FDA submissions, for which devices, and with what outcomes?
• Is regulatory affairs handled in-house or by an outside firm?
• How have the company's past regulatory milestones compared with its own plans?

Clinical Network and Academic Relationships

Device companies need clinical advisors and study sites, and those relationships often come from the founders' networks.

Questions to ask:

• Who are the clinical advisors, and what is their standing in the field?
• Have study sites and investigators committed to the pivotal study?
• Does the company have relationships with centers that would use the device?
• Has the team published or presented work in this area?

Commercial and Sales Execution

A good device can struggle with a weak go-to-market plan, and a device with a modest clinical advantage can do well with a team that understands hospital purchasing and clinical workflow.

Questions to ask:

• Does the sales leader have medtech and hospital sales experience?
• Has the team built a sales organization before, or is hiring planned after clearance?
• What is the go-to-market model: direct sales, distribution partners or both?
• Which clinicians are expected to champion adoption, and have their views been checked independently?

Operations and Quality

Supply chain, quality, regulatory compliance and financial management are less visible than the device itself, but they decide whether a company can scale.

Questions to ask:

• Who leads quality and operations, and what is their background?
• What is the status of the quality system against the QMSR and ISO 13485:2016?
• Has FDA inspected the company or its manufacturers, and what did it find?
• How disciplined are budgeting and forecasting?
• Could the company's records support an investor's or acquirer's diligence review?

How Vantage Structures a Full Report

Vantage full reports read a company across four areas and twenty categories, mapped to eight domains: regulatory, clinical, IP, reimbursement, commercial, team, financial and competitive position. Factual claims are cited to their sources, and each full report is reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME.

Each full report summarizes the eight domain scores in the Vantage Index, a composite with a confidence band for each domain, read against comparable companies. It summarizes the evidence; it is not a readiness verdict or a prediction. The specific scoring criteria and weights are proprietary; the category structure is published on our methodology page. For how the public records behind each area can be checked, see How to Verify a Medtech Claim in the Public Record.

Common Due Diligence Pitfalls

1. Reading Revenue Without Its Source

Early revenue can come from a small number of accounts, from research or evaluation use, or from sales under a narrower indication than the one being pitched. Separate commercial revenue from everything else, and check that it matches what the device is cleared or approved for.

2. Taking the Predicate at Face Value

A 510(k) plan can rest on a predicate with a different intended use, significant technological differences or a recall history. Check the predicate's record directly and get an independent regulatory read. See The Predicate Trap.

3. Treating Reimbursement as Automatic

Clearance does not create coding, coverage or payment. Model the reimbursement path as its own timeline, with scenarios for later or lower payment.

4. Underestimating Scale-Up

Supplier changes, yield problems and design rework can raise unit cost during scale-up. Ask for supplier quotes, yield data and the validation status of production processes.

5. Using the Company's Timeline Instead of Precedent

Clinical enrollment, FDA review and reimbursement all take time. Compare the plan with the public record for comparable devices and with the company's own record on past milestones.

6. Not Checking Clinical Support Independently

An advisory board listing is not evidence of adoption. Speak with clinicians who are not paid advisors about whether they would use the device.

Due Diligence Checklist

References

1. FDA. "Premarket Notification 510(k)." fda.gov
2. FDA. "De Novo Classification Request." fda.gov
3. FDA. "Premarket Approval (PMA)." fda.gov
4. FDA. "Breakthrough Devices Program." fda.gov
5. FDA. "Investigational Device Exemption (IDE)." fda.gov
6. FDA. "522 Postmarket Surveillance Studies Program." fda.gov
7. FDA. "Quality Management System Regulation (QMSR)." fda.gov
8. CMS. "Coverage with Evidence Development." cms.gov